Innovent Biologics Reports Strong Revenue Growth in Q3 2024
Company Announcements

Innovent Biologics Reports Strong Revenue Growth in Q3 2024

Innovent Biologics (HK:1801) has released an update.

Innovent Biologics saw a robust rise in its third-quarter 2024 revenue, surpassing RMB2.3 billion, marking a significant 40% increase from the previous year. The company attributes this growth to the strong performance of its oncology products, especially TYVYT, and the successful market launch of Dupert for lung cancer treatment. Innovent continues to strengthen its position in the biomedicine sector with a diverse product portfolio and strategic market penetration efforts.

For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskInnovent Biologics Ends Proposed Subscription Agreement
TheFlyInnovent Biologics says picankibart phase 2 study met primary endpoint
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App